CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
21 hedge funds and large institutions have $45.4M invested in CoLucid Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
108% more capital invested
Capital invested by funds: $21.8M → $45.4M (+$23.6M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 20 → 21 (+1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
37.15% less ownership
Funds ownership: 37.15% → 0% (-37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.15M |
| 2 |
SG Americas Securities
New York
|
+$275K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$263K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.1K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$48.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$2.41M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$167K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$123K |
| 4 |
Goldman Sachs
New York
|
-$58K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$56.6K |
CLCD Hedge Fund Activity: Q4 2015 in Review
21 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q4 2015, worth a combined $45.4M — up 108% from $21.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CLCD positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $1.15M. The largest seller was Pentwater Capital Management, cutting an estimated $2.41M.
- 21 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q4 2015, up from 20 in Q3 2015.
- Funds reported $45.4M of CoLucid Pharmaceuticals, Inc. stock for Q4 2015, up 108% quarter-over-quarter.
- 5 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q4 2015 and 4 closed out, a net change of +1 holder.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q4 2015 was EverPoint Asset Management, an estimated $1.15M added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q4 2015 was Pentwater Capital Management, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2015.